Abstract
Ras association domain family member 5 (RASSF5, also named NORE1) is an identified member of the RASSF gene family which could bind selectively to activate Ras and function as an antineoplastic effector in multiple cellular regulations. While highly expressed in majority of normal tissues, RASSF5 is epigenetically inactivated by promoter hypermethylation in numerous cancer cell lines and primary cancers, suggesting it as a potential tumor suppressor. Nevertheless, the physiologic significance of RASSF5 in tumorigenesis remains unclear. We performed a systematic literature review and assessment from PUBMED and MEDLINE databases in this article. RASSF5 is involved in a series of cellular responses including apoptosis, senescence, cell cycle regulation, differentiation and cell proliferation and the inactivation of RASSF5 has been implicated to participate in the oncogenesis, progression and poor prognosis of human cancers. In this review, we mainly elucidate the acknowledged structure, progress in the verified functions and research advances of RASSF5 and the probably relevant signaling pathways. Based on these evidences, potentiality of RASSF5 as a new therapeutic target for human cancers may play a significant role in future oncotherapy.
Keywords: RASSF5, tumor suppressor, promoter hypermethylation, therapeutic target, malignancy, apoptosis.
Anti-Cancer Agents in Medicinal Chemistry
Title:The Emerging Roles of RASSF5 in Human Malignancy
Volume: 18 Issue: 3
Author(s): Shuofeng Li, Jingwei Teng, Haiqing Li, Feifei Chen*Junnian Zheng*
Affiliation:
- Jiangsu Province Key Laboratory of Biological Cancer Therapy, Xuzhou Medical University, 84 West Huai-hai Road, Xuzhou 221002, Jiangsu,China
- Jiangsu Province Key Laboratory of Biological Cancer Therapy, Xuzhou Medical University, 84 West Huai-hai Road, Xuzhou 221002, Jiangsu,China
Keywords: RASSF5, tumor suppressor, promoter hypermethylation, therapeutic target, malignancy, apoptosis.
Abstract: Ras association domain family member 5 (RASSF5, also named NORE1) is an identified member of the RASSF gene family which could bind selectively to activate Ras and function as an antineoplastic effector in multiple cellular regulations. While highly expressed in majority of normal tissues, RASSF5 is epigenetically inactivated by promoter hypermethylation in numerous cancer cell lines and primary cancers, suggesting it as a potential tumor suppressor. Nevertheless, the physiologic significance of RASSF5 in tumorigenesis remains unclear. We performed a systematic literature review and assessment from PUBMED and MEDLINE databases in this article. RASSF5 is involved in a series of cellular responses including apoptosis, senescence, cell cycle regulation, differentiation and cell proliferation and the inactivation of RASSF5 has been implicated to participate in the oncogenesis, progression and poor prognosis of human cancers. In this review, we mainly elucidate the acknowledged structure, progress in the verified functions and research advances of RASSF5 and the probably relevant signaling pathways. Based on these evidences, potentiality of RASSF5 as a new therapeutic target for human cancers may play a significant role in future oncotherapy.
Export Options
About this article
Cite this article as:
Li Shuofeng, Teng Jingwei , Li Haiqing, Chen Feifei *, Zheng Junnian*, The Emerging Roles of RASSF5 in Human Malignancy, Anti-Cancer Agents in Medicinal Chemistry 2018; 18 (3) . https://dx.doi.org/10.2174/1871520617666170327120747
DOI https://dx.doi.org/10.2174/1871520617666170327120747 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes and aid in stabilizing chromosomal makeup. Resynthesis of telomeres supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no any telomerase activity in human somatic cells, but the stem cells and germ cells undergone telomerase ...read more
Role of natural compounds as anti anti-cancer agents
Cancer is considered the leading cause of worldwide mortality, accounting for nearly 10 million deaths in 2022. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy remains an important approach in treatment o f several types of cancers, even though ...read more
Signaling and enzymatic modulators in cancer treatment
Cancer accounts for nearly 10 million deaths in 2022 and is considered the leading cause of worldwide mortality. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy, radiotherapy and surgery are the most important approach for the treatment of several ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Anticipation in Lynch Syndrome: Where We Are Where We Go
Current Genomics Design, Synthesis, and Evaluation of Genistein Analogues as Anti-Cancer Agents
Anti-Cancer Agents in Medicinal Chemistry Potential Disease Targets for Drugs that Disrupt Protein - Protein Interactions of Grb2 and Crk Family Adaptors
Current Pharmaceutical Design TPEN Exerts Antitumor Efficacy in Murine Mammary Adenocarcinoma Through an H2O2 Signaling Mechanism Dependent on Caspase-3
Anti-Cancer Agents in Medicinal Chemistry Proteasome Inhibitors in Cancer Therapy and their Relation to Redox Regulation
Current Pharmaceutical Design Exploring the Role of Asp1116 in Selective Drug Targeting of CREBcAMP- Responsive Element-binding Protein Implicated in Prostate Cancer
Combinatorial Chemistry & High Throughput Screening Serenoa Repens, Lycopene and Selenium: A Triple Therapeutic Approach to Manage Benign Prostatic Hyperplasia
Current Medicinal Chemistry Potential Cancer Gene Therapy by Baculoviral Transduction
Current Gene Therapy Click Synthesis, Anticancer Activity and Molecular Docking Studies on Pyridazinone Scaffolds
Current Organic Chemistry Endothelial Effects of Drugs Designed to Treat Erectile Dysfunction
Current Pharmaceutical Design MicroRNAs in Tumorigenesis
Current Pharmaceutical Biotechnology Determination of Usnic Acid Responsive miRNAs in Breast Cancer Cell Lines
Anti-Cancer Agents in Medicinal Chemistry Evolution of Ipsilateral Head and Neck Radiotherapy
Current Cancer Therapy Reviews The Induction and Repair of DNA Interstrand Crosslinks and Implications in Cancer Chemotherapy
Anti-Cancer Agents in Medicinal Chemistry Alpha-1-Antitrypsin Deficiency Liver Disease and New Treatment Opportunities
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Synthesis and Biological Evaluation of Novel 1,3,4-thiadiazole Derivatives Incorporating Benzisoselenazolone Scaffold as Potential Antitumor Agents
Medicinal Chemistry Structure, Function, Involvement in Diseases and Targeting of 14-3-3 Proteins: An Update
Current Medicinal Chemistry Thiol-Activated Anticancer Agents: The State of the Art
Anti-Cancer Agents in Medicinal Chemistry Multifaceted Mechanisms for Cell Survival and Drug Targeting in Chronic Myelogenous Leukemia
Current Cancer Drug Targets Management of Inflammation by Natural Polyphenols: A Comprehensive Mechanistic Update
Current Medicinal Chemistry